ERBB2 and head and neck squamous cell carcinoma: Trials based on the adoptive transfer of immune cells engineered to target ErbB2, such as NK cells, macrophages or T cells, are also underway for patients with ErbB2-expressing tumors, including HNSCC (Table 2).